Mortality rate by Covid-19 in patients on chronic use of oral anticoagulants at a teaching hospital in western Paraná
DOI:
https://doi.org/10.52076/eacad-v4i2.453Keywords:
Anticoagulants; Disseminated; Intravascular; Coagulation; Coronavirus; COVID-19; SARS-CoV-2.Abstract
Fundamentals: COVID-19 is an infectious disease capable of stimulating a generalized procoagulative effect in the human body. Objectives: Evaluate the mortality rate from COVID-19 in patients on chronic use of oral anticoagulants admitted to a teaching hospital in western Paraná. Methods: We analyzed, retrospectively, 220 medical records of patients admitted for COVID-19, from January to October 2021. Then, we interpret the data comparatively, from the patients on chronic use of oral anticoagulants, those who did not use anticoagulants, those who started oral anticoagulation during the COVID-19 infection and those on continuous use of antiplatelet agent. Results: Of the 220 patients evaluated, 10 used anticoagulants chronically before COVID-19 (70±15 years old; 8±4 in-hospital stay) and, when compared with 196 patients who denied the use of anticoagulants (57±16 years old; 10±8 in-hospital stay), the anticoagulated group presented higher mortality (p=0.046) and was older (p=0.02). Likewise, when compared to the 17 patients who used continuous antiplatelet agents (72±9 years old; 13±9 in-hospital stay), the non anticoagulated group was younger (p<0.001) and presented a lower death rate (p=0.018). The 14 patients who started oral anticoagulation at the beginning of COVID-19 (51±15 years old; 14±14 in-hospital stay) were younger when compared to the group on chronic anticoagulation (p=0.009) and to the patients on continuous use of antiplatelet drugs (p<0.001), with similar death rates between these three groups. Conclusion: The study observed that continued use of oral anticoagulants prior to COVID-19 infection did not represent a protective factor in the mortality from the disease.
References
ALY, R. et al. The use of direct acting oral anticoagulants in patients with COVID-19 infection. J Community Hosp Intern Med Perspect. 2021;11(2):184-186. Published 2021 Mar 23. https://doi.org/10.1080/20009666.2020.1867295.
ANDERSON, E.L. et al. Consideration of the Aerosol Transmission for COVID-19 and Public Health. Risk Anal. 2020, may; 40: 902-907. https://doi.org/10.1111/risa.13500.
ASLAN, B. et al. The effect of chronic DOAC treatment on clinical outcomes of hospitalized patients with COVID-19. Int J Clin Pract. 2021;75(9):e14467. https://doi.org/10.1111/ijcp.14467.
BARNES, G.D.; MOULAND, E. Peri-Procedural Management of Oral Anticoagulants in the DOAC Era. Prog Cardiovasc Dis. 2018, apr; 60: 600-606. https://doi.org/10.1016/j.pcad.2018.03.002.
BRANDÃO, G.M.S. et al. Anticoagulantes orais diretos para o tratamento da trombose venosa profunda: revisão de revisões sistemáticas. Jornal Vascular Brasileiro [online]. 2018, v. 17, n. 4, pp. 310-317. https://doi.org/10.1590/1677-5449.005518.
BUENEN, A.G. et al. Prior use of anticoagulation is associated with a better survival in COVID-19. J Thromb Thrombolysis. 2021;52(4):1207-1211. https://doi.org/10.1007/s11239-021-02486-4.
CONNORS, J.M. Testing and monitoring direct oral anticoagulants. Blood. 2018, nov, 08; 132: 2009-1015. https://doi.org/10.1182/blood-2018-04-791541.
DENAS, G. et al. Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study. Int J Cardiol. 2021; 329:266-269. https://doi.org/10.1016/j.ijcard.2020.12.024.
EVANS, P.C. et al. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovasc Res. 2020;116(14):2177-2184. https://doi.org/10.1093/cvr/cvaa230.
FLAM, B. et al. Direct oral anticoagulant use and risk of severe COVID-19. J Intern Med. 2021;289(3):411-419. https://doi.org/10.1111/joim.13205.
FRÖHLICH, G.M. et al. Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany. Clin Res Cardiol. 2021;110(7):1041-1050. https://doi.org/10.1007/s00392-020-01783-x.
GAO, Y.D. et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428-455. https://doi.org/10.1111/all.14657.
GAVRIATOPOULOU, M. et al. Emerging treatment strategies for COVID‑19 infection. Clin Exp Med. 2021, may; 21: 167-179. https://doi.org/10.1007/s10238-020-00671-y.
HADID, T.; KAFRI, Z.; AL-KATIB, A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2021; 47:100761. https://doi.org/10.1016/j.blre.2020.100761.
HO, G. et al. Association of chronic anticoagulant and antiplatelet use on disease severity in SARS-COV-2 infected patients. J Thromb Thrombolysis. 2021;52(2):476-481. https://doi.org/10.1007/s11239-021-02383-w.
MORENO, G. et al. Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients. Med Intensiva. 2021, feb; 45: 42-55. https://doi.org/10.1016/j.medin.2020.06.006.
MOUSAVIZADEH, L.; GHASEMI, S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. Microbiol Immunol Infect. 2020, apr; 54: 159-163. https://doi.org/10.1016/j.jmii.2020.03.022.
PERICO, L. et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021, jan; 17: 46-64. https://doi.org/10.1038/s41581-020-00357-4.
RENTSCH, C.T. et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ. 2021;372:n311. Published 2021 Feb 11. https://doi.org/10.1136/bmj.n311.
RIVERA-CARAVACA, J.M. et al. Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. Thromb Res. 2021; 205:1-7. https://doi.org/10.1016/j.thromres.2021.06.014.
ROSSI, R. et al. Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era. Eur J Intern Med. 2020; 77:158-160. https://doi.org/10.1016/j.ejim.2020.06.006.
RUSSO, V. et al. Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study. Pharmacol Res. 2020; 159:104965. https://doi.org/10.1016/j.phrs.2020.104965.
SALIAN, V.S. et al. COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. Mol Pharm. 2021;18(3):754-771. https://doi.org/10.1021/acs.molpharmaceut.0c00608.
SCHUTGENS, R.E. DOAC in COVID-19: Yes or No? Hemasphere. 2020 Dec 29;5(1):e526. https://doi.org/10.1097/HS9.0000000000000526.
WOOL, G.D.; MILLER, J.L. The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology. 2021; 88: 15-27. https://doi.org/10.1159/000512007.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Karen Nataly Cemin; Jeferson Freitas Toregeani
This work is licensed under a Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
